Prolonged-release pirfenidone prevents myocardial fibrosis in a mouse nonalcoholic steatohepatitis model

Prolonged-release pirfenidone prevents myocardial fibrosis in a mouse nonalcoholic steatohepatitis model

Bibliographic Details
Main Authors:	J. Gutiérrez-Cuevas, A. Sandoval-Rodríguez, C. Monroy-Ramírez, A. Santos-García, J. Armendáriz-Borunda
Format:	Article
Language:	English
Published:	Elsevier 2020-09-01
Series:	Annals of Hepatology
Online Access:	http://www.sciencedirect.com/science/article/pii/S1665268120301022

Similar Items

Pirfenidone decreases insulin, glucagon, leptin, plasminogen activator inhibitor 1, preventing nonalcoholic steatohepatitis and myocarditis in an obesity moldel
by: Daniel López-Cifuentes, et al.
Published: (2024-02-01)

Prolonged-release pirfenidone decreases hepatic miRNAs expression in a NAFLD/NASH experimental model
by: R. Escutia-Gutiérrez, et al.
Published: (2020-09-01)

Pirfenidone slows the development of fibrosis and malignant neoplasms by modulating inflammation in an experimental model of hepatocarcinoma.
by: Scarlet Arceo-Orozco, et al.
Published: (2024-02-01)

Pirfenidone ameliorates MAFLD by improving insulin sensitivity and reducing epididymal fat
by: J. Gutiérrez-Cuevas, et al.
Published: (2022-12-01)

Cellular and molecular characterization of the pirfenidone effects on an hepatocarcinogésis experimental model
by: J.A. Silva-Gómez, et al.
Published: (2020-09-01)

Pirfenidone regulates antioxidant response via NRF2 in an experimental model of hepatocellular carcinoma
by: HC Monroy-Ramírez, et al.
Published: (2022-12-01)

Pirfenidone induces epigenetic changes modulating the activity of the ppargamma-SIRT1-DNMT1 axis in hepatic stellate cells
by: H.C. Monroy-Ramírez, et al.
Published: (2020-09-01)

P- 25 ANTIOXIDANT EFFECT OF MORINGA OLEIFERA IN A MURINE MODEL OF NONALCOHOLIC STEATOHEPATITIS
by: Alejandra Monraz-Méndez, et al.
Published: (2023-03-01)

Pirfenidone induces translocation of sirt1 to nucleus and deacetylation of histone 3 slows down the development of fibrosis and tumorigenicity in a experimental model of hepatocarcinoma.
by: Hugo C. Monroy-Ramírez, et al.
Published: (2024-02-01)

Analysis of the molecular interaction of pirfenidone with PPAR-gamma and effects on the beta-catenine pathway in HEPG2 line
by: H.C. Monroy-Ramírez, et al.
Published: (2020-09-01)

Nonalcoholic steatohepatitis (NASH) with diabetes: predictors of liver fibrosis
by: D.N. Amarapurkar, et al.
Published: (2006-01-01)

The administration of pirfenidone modifies the expression of JMJD2B in a murine model of NASH
by: JS Rodriguez Sanabria, et al.
Published: (2022-12-01)

Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis
by: Mehmet Sayiner, et al.
Published: (2018-11-01)

A simple method for inducing nonalcoholic steatohepatitis with fibrosis
by: Leyla Yahaghi, et al.
Published: (2019-12-01)

Circulating Citrate Is Associated with Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
by: Waseem Amjad, et al.
Published: (2023-08-01)

Pirfenidone Protects from UVB-Induced Photodamage in Hairless Mice
by: Yocasta Martinez-Alvarado, et al.
Published: (2023-03-01)

Transaminases and gamma glutamyl transpeptidase for detecting nonalcoholic steatohepatitis and fibrosis in nonalcoholic fatty liver disease
by: Shahinul Alam, et al.
Published: (2016-07-01)

P- 43 PIRFENIDONE PREVENTS NEOPLASTIC LESIONS DEVELOPMENT BY OXIDATIVE, FIBROGENIC, ANTIPROLIFERATIVE AND EPIGENETIC MECHANISMS REGULATION IN A MODEL OF CHEMICAL HEPATOCARCINOGENESIS
by: Hipólito Otoniel Miranda-Roblero, et al.
Published: (2023-03-01)

O-24 PIRFENIDONE PREVENTS NEOPLASTIC LESIONS DEVELOPMENT BY OXIDATIVE, FIBROGENIC, ANTIPROLIFERATIVE AND EPIGENETIC MECHANISMS REGULATION IN A MODEL OF CHEMICAL HEPATOCARCINOGENESIS
by: Hipólito Otoniel Miranda-Roblero, et al.
Published: (2023-03-01)

Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD/NASH
by: Rebeca Escutia-Gutiérrez, et al.
Published: (2021-06-01)

Plasma eicosanoids as noninvasive biomarkers of liver fibrosis in patients with nonalcoholic steatohepatitis
by: Cyrielle Caussy, et al.
Published: (2020-05-01)

Necroptosis in Nonalcoholic Steatohepatitis
by: Jérémie Gautheron, PhD, et al.
Published: (2015-05-01)

S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis
by: Mazo DF, et al.
Published: (2013-06-01)

Psoralea corylifolia L. Attenuates Nonalcoholic Steatohepatitis in Juvenile Mouse
by: Lishan Zhou, et al.
Published: (2017-11-01)

Health Care Use and Costs Among Patients With Nonalcoholic Steatohepatitis With Advanced Fibrosis Using the Fibrosis‐4 Score
by: Stuart C. Gordon, et al.
Published: (2020-07-01)

Orlistat for overweight subjects with nonalcoholic steatohepatitis.
by: Dowman, J, et al.
Published: (2009)

Fibrosis-4 index is associated with the risk of hepatocellular carcinoma in patients with cirrhosis and nonalcoholic steatohepatitis
by: Somaya Albhaisi, et al.
Published: (2023-08-01)

Increasing metabolic co-morbidities are associated with higher risk of advanced fibrosis in nonalcoholic steatohepatitis.
by: Robert J Wong, et al.
Published: (2019-01-01)

S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis [Corrigendum]
by: Mazo DF, et al.
Published: (2013-09-01)

IMAGING DIAGNOSIS OF NONALCOHOLIC STEATOHEPATITIS
by: Anca Smaranda Farmazon, et al.
Published: (2018-09-01)

Pathogenesis of Nonalcoholic Steatohepatitis: An Overview
by: Gopanandan Parthasarathy, et al.
Published: (2020-04-01)

Recent update: Nonalcoholic steatohepatitis
by: Vivek Hande, et al.
Published: (2018-01-01)

Editorial: Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies
by: Ana Sandoval-Rodriguez, et al.
Published: (2022-04-01)

Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond
by: Alberto Aimo, et al.
Published: (2022-04-01)

Role of pirfenidone in the management of pulmonary fibrosis
by: Meyer KC, et al.
Published: (2017-04-01)

Application of Pirfenidone anti-fibrosis in ophthalmology
by: Xiao Yang, et al.
Published: (2013-08-01)

Pirfenidone treatment of idiopathic pulmonary fibrosis
by: Arata Azuma
Published: (2012-04-01)

Pirfenidone treatment of idiopathic pulmonary fibrosis
by: Ye Gan, et al.
Published: (2011-02-01)

Familial Hypobetalipoproteinemia-Induced Nonalcoholic Steatohepatitis
by: Mindy C.W. Lam, et al.
Published: (2012-07-01)

Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western DietSummary
by: Souradipta Ganguly, et al.
Published: (2021-01-01)